Secondary analysis of ODYSSEY (381 children with HIV starting first-line ART): younger age, lower BMI-for-age and lower CD4% predicted treatment failure by 96 weeks; failure risk was lower on dolutegravir than standard care (HR 0.47; 75 failures).
Secondary analysisn = 381
Wyncoll et al. Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial